

Sub
C1
3. (Amended) A compound according to claim 1, wherein R₂ is selected from the group consisting of ethyl, ethenyl, ethynyl, propyl, 1-propenyl, 1-propynyl, 1,2-propadienyl, and cyclopropyl.

4. (Amended) A compound according to claim 1, wherein R₁ is oxo, R₃ is hydrogen, and the dotted lines indicate a Δ^4 double bond.

5. (Amended) A compound according to claim 1, wherein R₂ is ethyl or ethenyl.

6. (Amended) A compound according to claim 1, selected from the group consisting of (7 α ,17 β)-7,13-Diethyl-17-hydroxygon-4-en-3-one and (7 α ,17 β)-7-Ethenyl-13-ethyl-17-hydroxygon-4-en-3-one.

7. (Amended) The compound (7 α ,17 β)-7-ethyl-17-hydroxyestr-4-en-3-one (7 α -ethyl-19-nortestosterone). *dis*

9. (Amended) A pharmaceutical formulation according to claim 8, wherein R₂ is selected from the group consisting of ethyl, ethenyl, ethynyl, propyl, 1-propenyl, 1-propynyl, 1,2-propadienyl, and cyclopropyl.

10. (Amended) A pharmaceutical formulation according to claim 9, wherein the steroid compound is selected from the group consisting of (7 α ,17 β)-7-ethyl-17-hydroxyestr-4-en-3-one, (7 α ,17 β)-7,13-diethyl-17-hydroxygon-4-en-3-one, and (7 α ,17 β)-7-

dis

Sub
3
cont.
ethenyl-13-ethyl-17-hydroxygon-4-en-3-one.

AI
11. (Amended) A pharmaceutical formulation according to claim 8 suitable for oral administration.

13. (Amended) A kit for male contraception comprising a progestagen and an androgen, wherein the androgen is a compound according to claim 1.

Sub
C5
15. (Amended) A method of treatment according to claim 14, wherein R₂ is selected from the group consisting of ethyl, ethenyl, ethynyl, propyl, 1-propenyl, 1-propynyl, 1,2-propadienyl, and cyclopropyl.

16. (Amended) A method of treatment according to claim 15, wherein the steroid compound is selected from the group consisting of (7 α ,17 β)-7-ethyl-17-hydroxyestr-4-en-3-one, (7 α ,17 β)-7,13-diethyl-17-hydroxygon-4-en-3-one, and (7 α ,17 β)-7-ethenyl-13-ethyl-17-hydroxygon-4-en-3-one.